Drugs for entire world - "Zdravlje Actavis" starts trial production according to GMP standards

On Monday (August 27, 2007), Leskovac-based "Zdravlje Actavis" will start trial production in accordance with GMP standards.

In the new unit, of which modernization made it the best factory in the system of Icelandic pharmaceutical company, the fourth largest manufacturer of generic drugs in the world, regular production will start already in September.

The production will start with 12 charges of Ranisan by the standards of good production practice, which implies production in controlled environment, as well as quality and safe drug for end user. That opens the way for the preparations from this factory to the most demanding market of EU.

This will also represent a big turn for "Zdravlje Aktavis" in business policy: factory that used to sell 84% of products in Serbia will be now producing 75% of assortment for "Actavis".

After increase in production capacity from 650m in old unit to 2 - 2.5 billion in the new unit, everybody counts on export of 1.6 billion of pellets to all countries of the world, except to USA. That means that the export will grow from present 16% to 75%. Of course, the profit of the company will also be larger - 42-45 billion EUR.

- U modernizaciju pogona do sada je uloženo 15,5 mil EUR, računamo da ćemo završiti sa ukupno 25 miliona - navodi generalni direktor Goran Stojilković.